Next Article in Journal
Adverse Pathological Findings at Radical Prostatectomy following Active Surveillance: Results from the Movember GAP3 Cohort
Next Article in Special Issue
Real-World Experience of Measurable Residual Disease Response and Prognosis in Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine
Previous Article in Journal
Evaluation of the Perioperative and Postoperative Course of Surgery for Pineal Germinoma in the SIOP CNS GCT 96 Trial
Previous Article in Special Issue
Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 14
Issue 14
10.3390/cancers14143557
Review Report
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

NF-κB: A Druggable Target in Acute Myeloid Leukemia

Cancers 2022, 14(14), 3557; https://doi.org/10.3390/cancers14143557
by Barbara Di Francesco †, Daniela Verzella *,†, Daria Capece, Davide Vecchiotti, Mauro Di Vito Nolfi, Irene Flati, Jessica Cornice, Monica Di Padova, Adriano Angelucci, Edoardo Alesse and Francesca Zazzeroni
Reviewer 1: Anonymous
Reviewer 2:
Musa Yilmaz
Cancers 2022, 14(14), 3557; https://doi.org/10.3390/cancers14143557
Submission received: 6 July 2022 / Revised: 18 July 2022 / Accepted: 19 July 2022 / Published: 21 July 2022
(This article belongs to the Collection Acute Myeloid Leukemia (AML))

Round 1

Reviewer 1 Report

In this manuscript, Barbara & Verzella and colleagues reviewed NF-κB as a druggable target in Acute Myeloid Leukemia.

The article is well-written and comprehensive. I have several minor comments:

-          Line 321: I would argue that bortezomib is used routinely in AML, since the current treatment recommendations do not support its use. The citations here do not support the statement either. Perhaps there were some clinical trials worth mentioning, along with their results?

-          PIM kinases are NFkB-inducible oncogenes in AML able to promote survival of AML cells. I would recommend mentioning them in this review as well, since there is currently a quite successful clinical trial of SEL24/MEN1703 PIM inhibitor in AML pts.

-          The role of NFkB in LSCs is the most intriguing from the therapeutic point of view. Could the authors expand this topic more, e.g. in a separate section?

-          The translocation nomenclature should be updated according to the latest recommendations (e.g. BCR::ABL) see: https://www.nature.com/articles/s41375-021-01436-6

-          The subtitle 3.5 is missing a “5” before q

-          Minor English grammar and spelling mistakes should be corrected throughout the manuscript

Author Response

Please see the attachment

Author Response File: Author Response.docx

Reviewer 2 Report

This is a very nice comprehensive review of the NF-KB pathway in AML. My minor edits are listed below.

Line 28 – “while for people >60 years of age the prognosis remains uncertain….” Please correct, it is certainly worse, cure rates <20%

Line 46 – clarify, p65/p50 is part of NK Kapa B ? not listed in the prior sentence

Line 159 – in section 3.5, the subtitle “5q deletion” is misspelled as “q deletion”

Line 192 – FLT3 ITD misspelled

Line 240 – hyperactivation misspelled

Line 451 – tyrosine misspelled

Line 578 – radiotherapy?

 

Line 588 – 601 : recommend omitting section 12.2 Natural Compounds, essential oils.  No data presented about AML, does not add to this review. 

Author Response

Please see the attachment

Author Response File: Author Response.docx

Back to TopTop